Opus Genetics reports OPGx-BEST1 Phase 1/2 results
Opus Genetics announced 3-month results from the low dose cohort of its OPGx-BEST1 study, a gene therapy for BEST1-related retinal disease. The ongoing trial may impact clinical development timelines and investor sentiment for gene therapy stocks.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day